Pelthos Therapeutics Inc. Proceeds from Debt, Net of Issuance Costs
Pelthos Therapeutics Inc. (PTHS) reported Proceeds from Debt, Net of Issuance Costs of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2026-08-13
- Pelthos Therapeutics Inc. proceeds from debt, net of issuance costs for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Pelthos Therapeutics Inc. proceeds from debt, net of issuance costs for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Pelthos Therapeutics Inc. proceeds from debt, net of issuance costs for the quarter ending 2025-12-31 was $0.00.
- Pelthos Therapeutics Inc. proceeds from debt, net of issuance costs for the quarter ending 2025-09-30 was $68.00K.
- Pelthos Therapeutics Inc. proceeds from debt, net of issuance costs for fiscal 2025 was $693.00K, a 29.29% increase from fiscal 2024.
- Pelthos Therapeutics Inc. proceeds from debt, net of issuance costs for fiscal 2024 was $536.00K, a 166.66% increase from fiscal 2023.
- Pelthos Therapeutics Inc. proceeds from debt, net of issuance costs for fiscal 2023 was $201.01K.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month | Proceeds from Debt, Net of Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $68.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $0.00 10-Q/A · filed 2026-08-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $68.00K derived: sum of 3 quarters · filed 2026-08-13 | $443.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $68.00K derived: sum of 2 quarters · filed 2026-03-19 | $443.00K derived: sum of 3 quarters · filed 2026-08-13 | $693.00K 10-K · filed 2026-03-19 | |
| 2025-09-30 | $68.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $443.00K derived: sum of 2 quarters · filed 2026-08-13 | $693.00K 10-Q · filed 2025-11-13 | $539.00K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $375.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-13 | $625.00K 10-Q · filed 2026-08-13 | $471.00K derived: sum of 3 quarters · filed 2026-08-13 | -$294.42K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $250.00K 10-Q/A · filed 2026-08-13 | $96.00K derived: sum of 2 quarters · filed 2026-08-13 | -$669.42K derived: sum of 3 quarters · filed 2026-08-13 | ||
| 2024-12-31 | -$154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$919.42K derived: sum of 2 quarters · filed 2026-03-19 | $536.00K 10-K · filed 2026-03-19 | $536.18K 10-K · filed 2025-03-27 | |
| 2024-09-30 | -$765.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $690.00K 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $1.46M 10-Q · filed 2025-08-13 | ||||
| 2023-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $110.85K derived: sum of 2 quarters · filed 2025-03-27 | $201.01K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $90.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $181.01K 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $90.16K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |